TransCode Therapeutics (RNAZ) Stock: Buy, Sell, or Hold?
RNAZ - TransCode Therapeutics, Inc. Common Stock
$1.55
-0.14 (-8.04%)
▼
5d:
-6.36%
30d:
-25.0%
90d:
-79.8%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When RNAZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: RNAZ shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: RNAZ shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: RNAZ is currently trading at $1.54, which is considered oversold relative to its 30-day fair value range of $1.59 to $2.19.
Technical Outlook: Technically, RNAZ is in a strong downtrend. The price is currently testing key support at $1.52. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: RNAZ scores 64/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.00 (+547.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RNAZ is in a strong downtrend. The price is currently testing key support at $1.52. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: RNAZ scores 64/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.00 (+547.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.59 -
$2.19
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (64/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.0%)
- BULLISH: Trading 547.2% below Wall St target ($10.00)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.59 -
$2.19
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.52
Resistance Level
$2.39
Current Trend
Strong Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.83
Wall Street Target
$10.00
(+547.2%)
Share & Embed Analysis
Last updated: October 02, 2026 3:53 AM ET
Data refreshes hourly during market hours. Next update: 4:53 AM
Data refreshes hourly during market hours. Next update: 4:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNAZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 51 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 53 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$118 | 54 HOLD |
